In the ongoing TACTOPS study (TAA Specific Cytotoxic T Lymphocytes in Patients with Pancreatic Cancer; Clinical Trials.gov Identifier: NCT03192462), patients with PDAC receive cytotoxic T lymphocytes directed against a panel of tumour-associated antigens (TAA) including survivin. This evidence concerns the gene BIRC5 and pancreatic neoplasm.